Reshaping the HIV treatment and prevention landscape

Significant scale of change and delivery 2017-20 gsk Improved performance whilst investing in R&D Strengthened R&D and pipeline - 2017 2020 Sales £30.2bn £34.1bn Adj OP £8.6bn £8.9bn Op cash flow* £8.3bn £10.1bn - R&D** £3.9bn £4.6bn Optimised product portfolio and network (new GSK) - - - 44% to 60% sales in Vx/Spec 28% reduction in manufacturing sites On track for £1.5bn annual cost savings £1.4bn divestments^ 11 approvals since 2017 - top quartile - - - R&D spend per launch Median PYS per launch 95% success rate (P3/pivotal) Strong pipeline: 20 vaccines and 42 medicines. 22 in pivotal studies Created new world leader in Consumer Healthcare - - - — 2020 £10bn sales, 4% sales growth^^ 2 integrations completed to deliver >£1bn in annual cost savings Transformed portfolio. £4bn divestments 25% increase in adjusted OP Transformed commercial execution - — | £10bn annual new and specialty sales Industry leading launch from Shingrix Trelegy and 2DR > £1bn Growing revenue through Advair LoE Driving inflection points in mid-cycle assets Leading ESG performance and new culture progress - - - Global health, I&D, environment Top 125: 85% new in role since 2017, 31% external, 39% women; Science Top Employer Record levels of employee engagement New incentive scheme *Op cash flow: Cash generated from operations; ** Adjusted R&D ^Divestment proceeds are stated on pre-tax basis ^^CH sales growth is on pro forma basis and excludes brands divested / under review PYS Peak Year Sales 8

View entire presentation